BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 16, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AR9281: Phase IIa started

Arete began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate oral AR9281 in 150 treatment-naïve, pre-diabetic patients.

Read the full 75 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >